CSL stock went into this result having climbed over the past quarter, closing at A$157.82, yet the latest numbers land with a jolt. The global biotech giant posted a trailing twelve month loss from continuing operations of US$2.99b on revenue of US$15.80b. That kind of earnings squeeze grabs short term traders by the throat. For long term investors, the real question now is how to weigh that loss against analyst forecasts that point to a return to profitability, as well as the current gap between the share price and discounted cash flow fair value.
Love CSL’s global scale and revenue base but uneasy about a recent loss from continuing operations? Benchmark this result against 10 resilient stocks with low risk scores.
FY 2026 Earnings Summary
- Revenue (FY 2026 vs FY 2025, trailing twelve months): US$15,797 million vs. US$15,558 million (up 1.5%)
- Net Income or Loss (FY 2026 vs FY 2025, trailing twelve months): loss of US$2,579 million vs. profit of US$3,002 million (reversed from profit to loss)
- Basic EPS (FY 2026 vs FY 2025, trailing twelve months): US$5.35 loss per share vs. US$6.20 earnings per share (reversed from earnings to loss)
- Earnings from Continuing Operations (FY 2026 vs FY 2025, trailing twelve months): loss of US$2,986 million vs. profit of US$3,136 million (reversed from profit to loss)
Prefer clear charts instead of scrolling through dense earnings tables and raw figures? Get a complete visual overview of CSL’s recent loss and overall performance, with everything brought together in one simple dashboard via the company report for CSL.
CSL’s Rebuild Story Meets Mixed Execution Reality
The bullish story on CSL is that cost savings, a tighter portfolio and new launches can pull earnings out of a trough and rebuild margins. The latest numbers partly support that view but also show how early the rebuild still is. Revenue of US$15.80b and modest 1.5% growth keep the top line moving, so the portfolio is not stalling. Positive updates on ANDEMBRY in paediatric hereditary angioedema and fresh approvals for Privigen and HEMGENIX confirm that CSL is hitting key pipeline and launch milestones that back a broader market opportunity.
Against that, the shift from a US$3.00b profit to a US$2.58b loss and the US$2.99b loss from continuing operations underline that the targeted US$500 to US$550m in annual cost savings by FY28 are not yet flowing through. The operational rebuild is visible, but the earnings recovery leg of the bullish thesis is still unproven.
Compare CSL’s internal progress on new products and cost savings with how the street is reacting to the latest A$157.82 share price. See the consensus price target analysis for CSL to check whether analyst targets are lining up with that rebuilding story.CSL bears focus on cost savings and pipeline hits
The bearish view on CSL is that cost savings will arrive late or not at all, and that product and acquisition missteps will cap any earnings rebuild. This result gives that view fresh support. Revenue of US$15.80b with 1.5% growth leaves the top line intact, yet profit has moved from US$3.00b to a loss of US$2.58b and earnings from continuing operations have also shifted to a loss of US$2.99b. That indicates the targeted US$500 to US$550m annual savings by FY28 are not yet visible in the income statement.
On pipeline risk, positive Phase 3b data for ANDEMBRY and progress for Privigen and HEMGENIX challenge fears of broad clinical disappointment. However, the TAVNEOS sales at risk and prior Vifor impairments keep the acquisition and capital allocation concerns alive. The earnings trough is tangible. The fix still is not.
After a profit swing this sharp, are CSL’s debt load and dividend strain just early warnings? Review the full risk analysis for CSL which shows 2 important warning signsStay Ahead With CSL And Simply Wall St
If CSL’s swing from profit to loss has your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and watch for a potential entry point that fits your plan. After you own CSL or any other stock, use the Portfolio Command Center to cut through market noise and surface only the updates that matter to your holdings. For longer term investors who want perspective beyond the headlines, the Community lets you see how other investors are thinking about the same risks and catalysts. That way you can spot potential turning points early and stay a step ahead of the market.
Seeking Alternatives Beyond CSL Right Now
Fresh ideas move fast. Some stocks are building breakout momentum while others are dropping back under the radar for now. Spot them before the crowd and get in early.
- Catch income opportunities that mix yield with resilience using a curated set of 4 dividend fortresses before payouts or pricing shifts dull the edge of these ideas.
- Target resilient potential compounders by scanning a focused list of solid balance sheet and fundamentals stocks (21 results) while valuations and expectations still leave room for a cleaner entry.
- Track early leaders in AI profitability through a curated pool of 75 profitable AI stocks that aren't just burning cash before their numbers and momentum are fully caught by broader attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com